Clinical trials: Immunogenicity
Influenza
Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Healthy Adults.
- Trial name
- NCT00754455
- Testing
- Influenza VLP Vaccine (recombinant)
- Where
- 4 sites in United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine…
- Trial name
- COVID-19 (NCT05975060)
- Testing
- XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
- Where
- 30 sites in United States
- Volunteers
- 660 people
- Sponsor
- Novavax
HIV Infections
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with…
- Trial name
- NCT02207920
- Testing
- AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19
This is a first-in-human (FIH), randomized, double-blind, placebo-controlled, single-center phase I clinical trial of JS026 and JS026 + JS016 Injection.
- Trial name
- NCT05167279
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Respiratory Syncytial Virus Infection, Healthy Volunteers
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
- Trial name
- NCT06237296
- Testing
- RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1
- Where
- 17 sites in United States, Australia
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis…
- Trial name
- NCT00390910
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Infanrix hexa
- Where
- 8 sites in Greece, Spain
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable…
- Trial name
- NCT02289820
- Testing
- MEDI7510, IIV
- Where
- 5 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
COVID-19, SARS-CoV-2 Infection
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT05037097
- Testing
- ARCT-165, ARCT-154, ARCT-021
- Where
- 4 sites in United States, Singapore and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
To develop an effective vaccine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Clover Biopharmaceuticals is conducting a Phase 1 study (CLO-SCB-2019-001) in healthy volunteers to evaluate the…
- Trial name
- NCT04932824
- Testing
- SCB-2019
- Where
- Australia
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Influenza
Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines
The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may occur for up to six months after vaccination.
- Trial name
- NCT00197288
- Testing
- Influenza
- Where
- 15 sites in United States
- Volunteers
- 1,847 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infection
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to…
- Trial name
- NCT04206813
- Testing
- Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
- Trial name
- NCT00743652
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 21 sites in United States
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Pfizer
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
- Trial name
- NCT05912049
- Testing
- 9MW3811 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
COVID-19, Vaccine Reaction
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
This project is a prospective observational real-world study, recruiting and screening subjects who have completed 2 doses of the COVID-19 vaccine for more than 6 months and receive the third dose of the vaccine voluntarily into…
- Trial name
- NCT05493917
- Testing
- an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Tetanus, Acellular Pertussis
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years
The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and (measles mumps rubella) MMR vaccines, compared…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00871117
- Testing
- GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
- Where
- 11 sites in United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' MenACWY-TT vaccine administered at 6 years post-primary vaccination with either GSK Biologicals'…
- Trial name
- NCT01777308
- Testing
- Meningococcal conjugate vaccine GSK134612
- Where
- 8 sites in Australia
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Immunodeficiency Diseases (PID)
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD)
- Trial name
- NCT03116347
- Testing
- HYQVIA, KIOVIG, Cuvitru
- Where
- 20 sites in Czechia, Denmark and 6 more
- Volunteers
- 42 people
- Sponsor
- Baxalta now part of Shire
RSV Respiratory Syncytial Virus
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
- Trial name
- ARIES (NCT07717840)
- Testing
- AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
- Where
- 6 sites in United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adults
Safety Study of Seasonal Influenza Vaccine by Jet Injection
This research study involves testing of a device that can give injections (shots) without the use of a needle.
- Trial name
- NCT00987350
- Testing
- LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore